# Infinimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infinimmune

- Industry: Biotechnology
- Headquarters: Alameda, US
- Website: www.infinimmune.com
- Total disclosed funding: $87M
- Latest round: Series A (Aug 11, 2026)
- Investors on record: 12

## About

Founded in 2022 by Wyatt McDonnell (CEO), Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe, and based in California, US, Infinimmune, Inc. operates as a biotechnology research company that develops new methods for antibody drug discovery and development.  In August 2026, Infinimmune, Inc. raised USD 75 million in series A funding co-led by Regeneron Ventures and Playground Ventures, with participation from RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Wild Tree Ventures, Godfrey Capital, Pear VC, Civilization Ventures, Everbright Biofund, and Merck Global Health Innovation Fund.

The firm develops antibody-based drugs that address unmet medical needs by screening human samples containing B cells and reading and rewriting the antibody sequences present to create superior drug candidates. The company uses large datasets and sample cohorts to discover new targets and create new classes of secure and efficient antibody drugs.The company will use the August 2026 funding to accelerate clinical development of its two lead programs in atopic dermatitis, support advancement of additional programs addressing unmet clinical needs, and enable continued deployment of its antibody discovery platform.

## Funding rounds

- Series A, Aug 11, 2026, $75M — Merck Global Health Innovation Fund, Goldcrest Capital, RA Capital Management, Pear VC, Playground Ventures, Civilization Ventures, Godfrey Capital, Forge Life Science Partners, Wild Tree Ventures, Regeneron Ventures, Everbright Biofund
- Seed, Oct 10, 2022, $12M — Pear VC, Playground Ventures, Civilization Ventures, Axial VC

## Investors

- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Seed, Series A
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Seed, Series A
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Seed, Series A
- Axial VC (https://capitalatlas.ai/funds/axial-vc) — Seed
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A
- Goldcrest Capital (https://capitalatlas.ai/funds/goldcrest-capital) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Godfrey Capital — Series A
- Forge Life Science Partners (https://capitalatlas.ai/funds/forge-life-science-partners) — Series A
- Wild Tree Ventures (https://capitalatlas.ai/funds/wild-tree-ventures) — Series A
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series A
- Everbright Biofund (https://capitalatlas.ai/funds/everbright-biofund) — Series A